Press Releases
Date Title and Summary View
Mar 2, 2012 NEW HAVEN, Conn., March 2, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it plans to release fourth quarter and full year 2011 financial results on Thursday, March 8, 2012, before the m...
Mar 1, 2012 NEW HAVEN, Conn., March 1, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that members of the executive team will provide a corporate update at the following upcoming investor conferences: ...
Feb 16, 2012 NEW HAVEN, Conn., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that novel preclinical and clinical virology data on ACH-1625, a Phase 2 pan-genotypic protease inhibitor, was presen...
Feb 8, 2012 NEW HAVEN, Conn., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael Kishbauch, President and Chief Executive Officer of Achillion, will provide a corporate update at the fol...
Feb 3, 2012 NEW HAVEN, Conn., Feb. 3, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the promotion of Mr. Joseph Truitt to Senior Vice President of Business Development. Mr. Truitt maintains his position...
Jan 13, 2012 NEW HAVEN, Conn., Jan. 13, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Joseph Truitt, Senior Vice President of Business Development and Chief Commercial Officer of Achillion, will pre...
Jan 9, 2012 Once-daily ACH-1625 safe, well-tolerated and achieves 100% cEVR after 12 weeks of treatmentPilot study of ACH-1625 in HCV genotype 3 achieves maximal 3.68 log10 reductionACH-2684 safe, well tolerated and achieves HCV genotype 1 maximal 4.63 log10 reduction; Additional dosing on-going NEW HAVEN, Conn., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Achillion ...
Jan 4, 2012 NEW HAVEN, Conn., Jan. 4, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced today the receipt of a Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACH-1625 for the treatmen...
Dec 5, 2011 NEW HAVEN, Conn., Dec. 5, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported proof-of-concept data from its Phase 1b clinical trial of ACH-2928, a first-generation NS5A inhibitor, demonstrating th...
Nov 21, 2011 NEW HAVEN, Conn., Nov. 21, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that members of the Company's executive team will present at the upcoming 23rd Annual Piper Jaffray Health Care Confe...
FirstPrevious ...
7
... NextLast
Add to Briefcase = add release to Briefcase

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue